CURRENT ASPECTS OF THE TREATMENT OF TRUE ACANTHOLYTIC PEMPHIGUS
True pemphigus is a group of severe autoimmune bullous dermatoses characterized by a progressive course and involvement of the skin and mucous membranes. The etiopathogenesis is associated with the production of autoreactive IgG4 antibodies against intercellular components of the epidermis, leading to the formation of flaccid bullae and painful erosions. Modern diagnostic methods, including immunofluorescence, detection of autoantibodies, and histopathological examination, enable accurate verification of the diagnosis. Nevertheless, therapeutic approaches remain a subject of ongoing discussion and debate. Systemic corticosteroid therapy remains the first-line and treatmentof-choice approach. The addition of immunosuppressive agents can facilitate more prolonged remission and reduce the maintenance dosage of corticosteroids. However, systemic adverse effects significantly impair patients’ quality of life and treatment adherence, while withdrawal syndrome may develop following discontinuation of therapy. These challenges have stimulated the search for and selection of more effective immunomodulatory strategies. Biologic therapies aimed at suppressing B-cell-mediated antibody production, particularly when combined with intravenous immunoglobulin G infusions and selective immunoadsorption techniques, provide more stable and controllable therapeutic outcomes. Furthermore, these approaches are opening a new era of steroid-sparing maintenance immunosuppressive therapy. This article provides an overview of pathogenetically oriented treatment approaches based on clinical protocols, guidelines, and randomized clinical trials published by international dermatological associations.
Сведения
- Опубликовано
- 2026 · Т. 26, № 5, С. 19-26
- Язык
- Английский
- ISSN
- 1694-500X · 1694-6839
- Издатель
- State Educational Institution of Higher Vocational Education Kyrgyz-Russian Slavic University